How Safe Is Hormone Replacement Therapy? What Women Should Know Now

Written By Kristina Calligan

Many women still hear old, scary messages about hormone replacement therapy (HRT): “Use the lowest dose for the shortest amount of time,” or “If you are more than five years from menopause, estrogen is off the table.”

Today, that conversation has changed.

How Safe Is Hormone Replacement Therapy? What Women Should Know Now

Hormone therapy is no longer one blanket “yes” or “no.” The safer question is: What symptom are we treating? Are we using localized or systemic estrogen? Do you have a uterus? What is your personal and family history? What route, dose, and formulation makes sense?

Estrogen is usually the main hormone women ask about when they ask if HRT is safe. It can be effective for hot flashes, night sweats, sleep disruption related to vasomotor symptoms, vaginal and urinary symptoms, and prevention of bone loss. But the type of estrogen therapy matters.

Localized vs. Systemic Estrogen: Why the Difference Matters

Localized estrogen is used primarily for vaginal, vulvar, bladder, and sexual symptoms caused by lower estrogen levels. This is often called genitourinary syndrome of menopause, or GSM. Symptoms may include vaginal dryness, burning, irritation, pain with intercourse, urinary urgency, and recurrent urinary tract infections. Localized estrogen may come as a vaginal cream, tablet, insert, or ring. These low-dose options are designed to work mainly in the vaginal and vulvar tissues, not throughout the whole body.

That distinction matters. Low-dose vaginal estrogen does not treat hot flashes or night sweats, but it can be very helpful for GSM. Because systemic absorption is minimal, progesterone is usually not needed for uterine protection when low-dose local vaginal estrogen is used. The Menopause Society has also stated that low-dose vaginal estrogen may be used at any age and for extended duration when needed.

Systemic estrogen is different. It travels through the bloodstream and can treat whole-body menopause symptoms such as hot flashes, night sweats, and related sleep disruption. It may also help protect bone.

Systemic estrogen may come as a patch, pill, gel, spray, or certain rings. Transdermal estrogen, such as a patch, avoids first-pass liver metabolism and may be a better fit for some women with clotting or cardiovascular risk factors. That does not mean it is risk-free; it means the route can be personalized.

If a woman has a uterus and uses systemic estrogen, she also needs adequate progesterone or a progestin to protect the uterine lining. Estrogen alone can stimulate the endometrium and increase the risk of endometrial hyperplasia or cancer. If a woman has had a hysterectomy, progesterone is often not needed.

What Does the Research Say About Breast Cancer Risk?

One of the biggest fears about estrogen is breast cancer. This is where the details matter. Early headlines after the Women’s Health Initiative created a long-lasting belief that all hormone therapy significantly increases breast cancer risk. But the data are more nuanced. In long-term WHI follow-up, estrogen-alone therapy in women with prior hysterectomy was associated with lower breast cancer incidence and mortality compared with placebo. In contrast, estrogen plus medroxyprogesterone acetate was associated with higher breast cancer incidence. This does not mean estrogen is “protective” for every woman; it means estrogen alone is not the same as estrogen plus certain progestins.

Who May Need a More Individualized Risk Discussion?

What about women who are considered high risk, such as those with a strong family history of breast cancer or a BRCA mutation? A family history or genetic risk does not automatically mean estrogen is forbidden. The 2022 Menopause Society position statement notes that available data do not show an additive effect of underlying breast cancer risk, including family history or genetic risk, and hormone therapy use on breast cancer incidence. It also notes that observational evidence suggests hormone therapy does not further increase breast cancer risk in women with a family history or after risk-reducing ovary removal for BRCA1 or BRCA2.

Newer data continue to be reassuring for many BRCA carriers after risk-reducing bilateral oophorectomy. A 2026 JAMA Network Open cohort study of 919 women with BRCA1 or BRCA2 pathogenic variants found that hormone therapy after risk-reducing ovary removal was not associated with increased breast cancer risk. Estrogen-only therapy was associated with lower breast cancer risk among women with BRCA1 in that study. These decisions should still be individualized and may involve a genetics provider, breast specialist, gynecologist, or oncologist.

It is also important to separate “high risk” from “personal history of breast cancer.” A woman with a family history or BRCA mutation is not the same as a woman currently being treated for breast cancer or with a prior estrogen-sensitive breast cancer. Systemic hormone therapy is generally avoided in women with a personal history of hormone-sensitive breast cancer unless managed with oncology involvement. Low-dose vaginal estrogen may still be discussed for severe GSM after nonhormonal options, using shared decision-making.

Timing, Duration, and the Right Treatment Plan

The rules about timing and duration have changed too. The old phrase “lowest dose for the shortest amount of time” was meant to encourage safety, but it often became too restrictive. Current guidance is more individualized: use the right dose, route, and formulation for the right patient, with periodic reevaluation. For healthy women under age 60 or within 10 years of menopause onset, the benefit-risk ratio is generally favorable when treating bothersome menopause symptoms and preventing bone loss. Being more than five years from menopause is not an automatic “no.” Even after age 60 or beyond 10 years from menopause, hormone therapy is not automatically forbidden, but the risk-benefit discussion becomes more careful.

A few quick notes about progesterone and testosterone: progesterone is primarily used to protect the uterus when systemic estrogen is prescribed to someone with a uterus, and the type of progesterone matters. Progesterone creams are not considered reliable for uterine lining protection. Testosterone is not estrogen therapy; it may be considered for carefully selected women with distressing low desire after evaluation, but dosing and monitoring matter.

The bottom line

Estrogen therapy is not one-size-fits-all. For many women, especially when therapy is individualized, estrogen can be a safe and effective option. At Arcadia Women’s Wellness, Julia Cyr, DNP, and Kristina Calligan, FNP, help patients understand fear-based myths versus evidence-informed care so they can make decisions with confidence.

Ready for clear, evidence-informed women’s health education? Sign up for the Arcadia Women’s Wellness blog below for weekly guidance on hormones, menopause, sexual health, prevention, and personalized wellness. You can schedule an appointment with Arcadia Women’s Wellness here.

Medical disclaimer: This article is for education only and does not replace individualized medical advice.

 

Sources:

Kristina Calligan
Previous

Why Estrogen Matters: What the Data Says About Menopause and Long-Term Health
Next

I Have an Abnormal Pap — Now What?